Background: Growing evidence indicates that major depressive disorder (MDD) is characterized by accelerated biological aging, including greater age-related changes in physiological functioning. The disorder is also associated with abnormal neural reward circuitry, particularly in the basal ganglia (BG). Here we assessed age-related changes in BG volume in both patients with MDD and healthy control participants.
Methods: We obtained whole-brain -weighted images from patients with MDD and healthy controls. We estimated grey matter volumes of the BG, including the nucleus accumbens, caudate, pallidum and putamen. Volumes were assessed using multivariate analysis of covariance (MANCOVA) with age as a covariate, followed by appropriate post hoc tests.
Results: We included 232 individuals (116 patients with MDD) in our analysis. The MANCOVA yielded a significant group × age interaction ( = 0.043). Analyses for each region yielded a significant group × age interaction in the putamen (univariate test, = 0.005; permutation test, = 0.004); this effect was not significant in the other regions. The negative association between age and putamen volume was twice as large in the MDD than in the control group (-35.2 v. -16.7 mm/yr), indicating greater age-related volumetric decreases in the putamen in individuals with MDD than in controls.
Limitations: These findings are cross-sectional; future studies should assess the longitudinal impact of accelerated aging on anhedonia and neural indices of reward processing.
Conclusion: Our results indicate that putamen aging is accelerated in patients with MDD. Thus, the putamen may uniquely contribute to the adverse long-term effects of depressive psychopathology and may be a useful target for the treatment of MDD across the lifespan.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5403661 | PMC |
| http://dx.doi.org/10.1503/jpn.160010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increased atherogenicity in mood disorders: a systematic review, meta-analysis and meta-regression.
Neurosci Biobehav Rev
January 2025
Department of Psychiatry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Psychiatry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, the Thai Red Cross Society, Bangkok, Thailand; Sichuan Provincial Center for Mental Health, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu 610072, China; Key Laboratory of Psychosomatic Medicine, Chinese Academy of Medical Sciences, Chengdu, 610072, China; Cognitive Impairment and Dementia Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand; Department of Psychiatry, Medical University of Plovdiv, Plovdiv, Bulgaria; Research Institute, Medical University Plovdiv, Plovdiv, Bulgaria; Research and Innovation Program for the Development of MU - PLOVDIV- (SRIPD-MUP), Creation of a network of research higher schools, National plan for recovery and sustainability, European Union - NextGenerationEU; Kyung Hee University, 26 Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea. Electronic address:
Background: Major depressive disorder (MDD) and bipolar disorder (BD) often coexist with metabolic syndrome. Both are linked to increased atherogenicity and a higher risk of cardiovascular diseases. Nevertheless, a comprehensive analysis of key atherogenic biomarkers in MDD/BD is still lacking.
View Article and Find Full Text PDFDistinction in the function and microstructure of white matter between major depressive disorder and generalized anxiety disorder.
J Affect Disord
January 2025
Department of Neurology, the First Affiliated Hospital of Anhui Medical University, Hefei 230022, China; Anhui Province Key Laboratory of Cognition and Neuropsychiatric Disorders, Hefei 230032, China; School of Mental Health and Psychological Sciences, Anhui Medical University, Hefei 230032, China; Collaborative Innovation Center of Neuropsychiatric Disorders and Mental Health, Hefei 230032, China; Institute of Artificial Intelligence, Hefei Comprehensive National Science Center, Hefei 230088, China.
Background: Major depressive disorder (MDD) and generalized anxiety disorder (GAD) are two of the leading causes of impairment to human mental health. These two psychiatric disorders overlap in many symptoms and neurobiological features thus difficult to distinguish in some cases.
Methods: We enrolled 102 participants, comprising 40 patients with MDD, 32 patients with GAD and 30 matched healthy controls (HCs), to undergo multimodal magnetic resonance imaging (MRI) scans.
Proteomic patterns associated with ketamine response in major depressive disorders.
Cell Biol Toxicol
January 2025
Research Institute, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, 510370, China.
Background: Major depressive disorder (MDD) is characterized by persistent feelings of sadness and loss of interest. Ketamine has been widely used to treat MDD owing to its rapid effect in relieving depressive symptoms. Importantly, not all patients respond to ketamine treatment.
View Article and Find Full Text PDFAlgorithm-informed treatment from EEG patterns improves outcomes for patients with major depressive disorder.
J Family Med Prim Care
December 2024
Department of Psychiatry and Behavioral Health, Jersey Shore University Medical Center, Neptune, NJ, USA.
Objective: Selecting the right medication for major depressive disorder (MDD) is challenging, and patients are often on several medications before an effective one is found. Using patient EEG patterns with computer models to select medications is a potential solution, however, it is not widely performed. Therefore, we evaluated a commercially available EEG data analysis system to help guide medication selection in a clinical setting.
View Article and Find Full Text PDF[The mediational role of cognitive function on occupational outcomes in persons with major depressive and bipolar disorder].
CNS Spectr
January 2025
Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Background: Improving functioning in adults with major depressive disorder (MDD) and bipolar disorder (BD) is a priority therapeutic objective.
Methods: This retrospective post hoc secondary analysis evaluated 108 patients with MDD or BD receiving the antidepressants vortioxetine, ketamine, or infliximab. The analysis aimed to determine if changes in objective or subjective cognitive function mediated the relationship between depression symptom severity and workplace outcomes.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!